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Background: Although altered levels of adiponectin have been reported as a potential risk factor in colorectal
cancer (CRC), the importance of the role played by adiponectin in colorectal carcinogenesis has not been
established. We sought to examine the expression pattern of adiponectin and adiponectin receptors (AdipoRs)
in the normal-adenoma-carcinoma sequence and to assess the implications of adiponectin in colorectal carcinogenesis.
Methods: Serum adiponectin concentrations, and the mRNA and protein expression of adiponectin and AdipoRs were
examined using serum and tissues from patients with CRC, advanced adenoma, and a normal colon. mRNA expression
of AdipoRs and epithelial-mesenchymal transition regulators including E-cadherin, cyclooxygenase-2 (COX-2) and
T-cadherin were examined in HCT116 cells treated with adiponectin.
Results: Serum adiponectin concentrations in patients with advanced adenoma and CRC were lower than those in
controls. Adiponectin mRNA was not detected in colonic tissue, whereas AdipoRs mRNA was lower in advanced
adenoma and CRC than that in normal colon tissues. Immunohistochemical staining demonstrated that adiponectin was
expressed in spindle-shaped cells of the subepithelial layer in normal colon tissues, whereas ill-defined overexpression of
adiponectin was seen in the stroma of advanced adenoma and CRC tissues. AdipoRs expression was strong in normal
epithelium, but weak to negative in the epithelia of CRC tissues. Adiponectin downregulated COX-2 mRNA expression
in vitro, but upregulated T-cadherin in HCT116 cells.
Conclusions: Systemic adiponectin and local AdipoRs expression in the colon may be associated with anti-tumorigenesis
during the early stages of CRC. These findings offer new insight into understanding the relationship between adiponectin
and colorectal carcinogenesis.
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Until quite recently, adipose tissue was regarded simply
as an energy store. However, it is now considered to be
an important endocrine organ, secreting a wide range of
biologically active adipokines [1]. Adiponectin is the
most abundant adipokine secreted from adipocytes; it is
a 30-kDa adipokine composed of 244 amino acids [2-5].
Serum adiponectin level is inversely correlated with vis-
ceral obesity [5-8]. It is also known to have anti-diabetic,
anti-inflammatory, and anti-atherosclerotic properties
[2,5,9,10]. Its action is mediated by binding to two main* Correspondence: kimse@ewha.ac.kr
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third adiponectin receptor, T-cadherin. AdipoR1 is ex-
pressed abundantly in skeletal muscle, whereas AdipoR2
is expressed predominantly in hepatocytes [5]. T-cadherin
was identified as a receptor for the hexameric and high
molecular weight species of adiponectin on vascular cells,
not for the trimetric or globular species [11].
Epidemiological studies have consistently reported a sig-
nificant link between obesity and malignancy [12-14]. Adi-
ponectin is secreted mainly from adipocytes and has
received considerable attention in relation to carcinogen-
esis in various cancers, including breast cancer, endomet-
rial cancer, and hepatocellular carcinoma [15-17]. Several
studies have demonstrated that adiponectin may have
anti-proliferative properties in terms of carcinogenesis [8].. This is an Open Access article distributed under the terms of the Creative
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(n = 10) (n = 29) (n = 39)
Age, years 0.091
Mean ± SD 54.5 ± 7.6 54.5 ± 7.6 60.2 ± 11.5
Gender (%) 0.108
Female 4 (40.0) 5 (17.2) 16 (41.0)
Male 6 (60.0) 24 (82.8) 23 (59.0)
Body mass index, kg/m2 0.811
Mean ± SD 22.8 ± 2.4 23.9 ± 3.8 23.5 ± 2.8
Location (%) 0.930
Cecum 1 (3.4) 1 (2.6)
Ascending colon 4 (13.8) 6 (15.3)
Hepatic flexure 2 (6.8) 1 (2.6)
Transverse colon 4 (13.8) 4 (10.3)
Descending colon 1 (3.4) 3 (7.8)
Sigmoid colon 7 (20.8) 15 (38.4)
Rectum 10 (38.0) 9 (23.0)
TNM Stage (%)
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eration in colorectal cancer cells. The effect of adiponectin
has been evaluated in Caco 2, DLD 1, LoVo, SW480, and
SW620 colorectal cancer cells but not in HCT119 and
HT29 cells [8,18,19], although one study showed that adi-
ponectin stimulates proliferation in HT29 cells [20].
However, the role of adiponectin in colorectal carcino-
genesis in humans has not been established. In a prospect-
ive study, serum adiponectin concentration was associated
with the risk of colorectal cancer (CRC) in males [21].
However, no association between serum adiponectin and
CRC was observed in another study [22].
No study has compared the tissue expression patterns
of adiponectin in normal-adenoma-carcinoma sequence
of the colon, although differences in the expression of the
two AdipoRs between normal colon epithelium and CRC
have been reported [23,24]. Whether the effects of adipo-
nectin in colorectal carcinogenesis are indirect, through
mediators such as insulin and inflammatory factors, and/
or direct, through actions on cancer cells is also unclear
[23]. Only one study has suggested that AdipoR1 nega-
tively regulates the epithelial-mesenchymal transition
(EMT) in breast cancer [25].
Thus, we investigated changes in adiponectin and Adi-
poRs in the normal-adenoma-carcinoma sequence of the
human colon. We also assessed the direct influence of adi-
ponectin on AdipoRs and EMT regulators including E-
cadherin, and cyclooxygenase-2 (COX-2), and T-cadherin
as a tumor suppressor, and not only a third adiponectin
receptor, in colon cancer cells.
Methods
Study population
Tissue samples were obtained from 39 patients with CRC
who underwent surgical resection or endoscopic removal,
29 patients with colorectal advanced adenoma (≥2 cm)
who underwent polypectomies, and 10 healthy subjects
with no colorectal pathological signs as a control group
from a single institute between 2009 and 2011 (Table 1).
Colonoscopy was performed on each subject in the mor-
ning before undergoing any surgical or endoscopic treat-
ment, and at least two pieces of tissue for quantitative
real-time polymerase chain reaction (qRT-PCR) were
taken from the lesion and macroscopically normal mu-
cosa. Additionally, two or three pieces of tissue was taken
during colonoscopy for immunohistochemical staining in
the control group, whereas surgical tissue sections were
obtained after operations or endoscopic procedures in the
advanced adenoma and CRC groups.
The medical records of each subject were reviewed for
the following information: age, gender, body mass index
(BMI), co-morbidity, presence or absence of diabetes
mellitus, and pathological characteristics, such as loca-
tion of cancer, and TNM stage. TNM staging wasassessed according to the 7th edition of the American
Joint Committee on Cancer stage classification system
[25]. BMI was calculated as weight divided by height2
(kg/m2) at the time of tissue sampling. According to the
International Obesity Task Force for Asian adults [26],
the normal weight and overweight groups were divided
by a BMI cut-off of 23 kg/m2.
Participants with diabetes mellitus, BMI ≥30 kg/m2, or
a severe accompanying disease, such as another cancer
except CRC, major organ insufficiency, infectious dis-
ease, and inflammatory bowel disease were excluded.
All included patients provided written informed con-
sent. This study was approved by the Institutional Re-
view Board of Ewha Womans University MokDong
Hospital (ECT205-9).
Measurement of serum adiponectin
Blood samples were obtained from all subjects at the
time of diagnosis in the morning. The Quantikine Hu-
man Adiponectin assay (R&D Systems, Minneapolis,
MN, USA) was used to measure adiponectin levels. All
assays were performed in duplicate. The normal range of
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(mean, 8,841) according to the manufacturer’s data.Measurement of tissue adiponectin and AdipoRs mRNA
expression
Total RNA was extracted from biopsy tissues using the
easy-BLUE (iNtRON Biotechnology, Sungnam, Korea)
total RNA extraction kit. The amount and purity of ex-
tracted RNAs were determined using spectrophotom-
etry. Complementary DNA samples were prepared by
reverse transcription using 2 μg RNA in each sample.
The full-length adiponectin and globular adiponectin
mRNA expression was carried out using SYBR Green
Master Mix (Applied Biosystems, Foster City, CA, USA).
The primers were: 5′-CTGGTGAGAAGGGTGAGAA
A-3′ (forward) and 5′-CTTCTTGAAGAGGCTGACC
T-3′ (reverse) for full-length adiponectin, and 5′-AACA
TGCCCATTCGCTTTAC-3′ (forward) and 5′-ATTAC
GCTCTCCTTCCCCAT-3′ (reverse) for globular adipo-
nectin.
qRT-PCR for the AdipoRs was carried out using Taq-
Man Expression Master Mix (Applied Biosystems). The
AdipoRs primers and probes were: the FAM-labeled
Adiponectin Receptor1 (assay ID Hs00360422_m1) was
used for AdipoR1, and the FAM-labeled Adiponectin
Recptor2 (assay ID Hs00226105_m1) was used for Adi-
poR2. The geometric mean of two validated reference
genes, including GAPDH (assay ID Hs99999905_m1)
and β2 microglobulin (assay ID Hs99999907_m1), was
used to adjust the expression of AdipoR1 and AdipoR2
in the qRT-PCR analysis. qRT-PCR was performed using
a Real-Time 7000 system (Applied Biosystems). A non-
template control was included in each experiment. All
patient samples and non-template controls were assayed
in duplicate.Measurement of adiponectin and AdipoRs protein
expression in tissues and cell lines
Tissues and cell lysates were prepared in ice-cold PRO-
PREP (Intron Biotech) and cleared by centrifugation
(12,000 rpm, 30 min, 4°C). The protein concentration in
each sample was estimated using the Bradford assay.
Each protein sample (25 μg) was resolved on 10% so-
dium dodecyl sulphate-polyacrylamide gel electrophoresis,
and transferred to a polyvinylidene fluoride membrane.
The membrane was incubated for 1 h in blocking solution
(5% non-fat milk in PBST) and incubated with primary
antibodies for 3 h at room temperature. Primary anti-
bodies included those against adiponectin (1:500; R&D
Systems) and GAPDH (1:10,000; Fitzgerald Industries
International Inc., Westborough, MA, USA). The blots
were washed in PBST and incubated with HRP-conjugated
secondary antibodies for 1 h at room temperature. Resultswere visualized using an enhanced chemiluminescent sys-
tem (Invitrogen, Carlsbad, CA, USA).Immunohistochemical staining for adiponectin and
AdipoRs in tissues
Immunohistochemistry was performed using the biotin-
streptavidin method with the LSAB Kit (Dakocytomation,
Carpentaria, CA, USA). Paraffinized tissues were sectioned
at 4 μm thickness and deparaffinized with xylene twice for
5 min. The tissues were dehydrated in an ethanol series
(100-70%) for 5 min each, and washed with distilled water.
Antigene retrieval conditions included heat-induced epi-
tope retrieval in 10 nM citrate buffer (pH 6.0) for 7 min.
Endogenous peroxidase activity was blocked by incuba-
ting the sections in 3% hydrogen peroxide solution for
5 min. The tissues were incubated with the monoclonal
anti-adiponectin (1: 250; R&D Systems), AdipoR1 (1:700;
Phoenix Pharmaceutical, Burlingame, CA, USA), and Adi-
poR2 (1:300; Phoenix Pharmaceutical) in a moist chamber
for 1 h at room temperature. The negative control was in-
cubated with diluent and background reducing compo-
nents (ready-to-use, Dakocytomation) instead of primary
antibody. Subsequently, the tissues were incubated for
30 min with a biotinylated immunoglobulin secondary
antibody solution. The tissues were then incubated with
streptavidin peroxidase solution for 30 min, and a liquid
DAB substrate chromogen solution was used as a sub-
strate to yield the brown-colored reaction products.
Hematoxylin staining was performed as a counter stain.
The stained tissues were photographed using an Olympus
microscope with ColorView3 digital camera (Soft Imaging
system, Gebh, Germany).
Adiponectin and AdipoRs expression were graded in
terms of density and distribution to analyze the data. Stai-
ning of epithelial cells was classified as none, mild, mode-
rate, or intense. The expression distribution was quantified
as the percentage of positive epithelial cells and assigned to
one of the following four categories: <10%, 10-30%, 30-60%
or >60%.
Each lesion was examined and scored independently by
a reviewer blinded to the patient information. Every sus-
pected pathological result was reviewed by a pathologist.Cell culture
HCT116, HT29, and CCD-18Co cells were obtained
from the Korean Cell Line Bank (KCLB, Seoul, Korea).
The cell lines were cultured in RPMI 1640 or DMEM.
All media were supplemented with 10% fetal bovine
serum (FBS) (v/v) and 1% penicillin/streptomycin. Cell
cultures were incubated in a CO2 incubator with a hu-
midified atmosphere of 95% air/5% CO2 at 37°C. Cul-
tures generally reached 80-90% confluence at 2–4 days
after seeding. After they reached confluence, the cells
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trypsin-EDTA.
Adiponectin treatment of the cell lines
HCT116 cells were plated in 12-well tissue culture
dishes at a density of 1 × 105 or 2 × 105 per well. The
cells were allowed to adhere overnight and were treated
with recombinant human full-length adiponectin (Bio-
Vendor Laboratory Medicine, Modrice, Czech Republic)
at 0.1, 1, or 20 μg/mL in FBS-containing medium for
24 h. Subsequently, the medium was discarded, and the
cells were washed with PBS before RNA extraction.
Measurement of AdipoRs, E-cadherin, COX-2, and
T-cadherin mRNA expression in adiponectin-treated cells
Total RNA was extracted from HCT116 cells using the
easy-BLUE (iNtRON Biotechnology) total RNA extrac-
tion kit. The amount and purity of the extracted RNAs
were determined by spectrophotometry. Complementary
DNA samples were prepared by reverse transcription using
2 μg RNA per sample. qRT-PCR was carried out using the
TaqMan Expression Master Mix (Applied Biosystems) for
AdipoRs. The primers used were as follows: the FAM-
labeled Adiponectin Receptor1 (assay ID Hs00360422_m1)
was used for AdipoR1 and the FAM-labeled Adiponectin
Recptor2 (assay ID Hs00226105_m1) was used for Adi-
poR2. qRT-PCR was carried out using the SYBR Green
Master Mix (Applied Biosystems) for E-cadherin, COX-2,
and T-cadherin. The primers used were: 5′-TGGGTTAT
TCCTCCCATCAG-3′ (foward) and 5′-TTTGTCAGGGA
GCTCAGGAT-3′ (reverse) for E-cadherin, 5′-TTCAAA
TGAGATTGTGGAAAAAT-3′ (forward) and 5′- AGATC
ATCTCTGCCTGAGTATCTT-3′ (reverse) for COX-2
and 5′- GATGTTGGCAAGGTAGTCGAT-3′ (forward)
and 5′-GCTCCCTGTGTTCTCATTGAT-3′ (reverse) for
T-cadherin. Expression levels were presented as a ratio to
GAPDH (assay ID Hs99999905_ml) as the internal con-
trol. qRT-PCR was performed using a Real-Time 7000
system (Applied Biosystems). A non-template control
was included in each experiment. All patient samples
and non-template controls were assayed in duplicate.
Statistical analyses
All statistical calculations were performed using SPSS
ver. 18.0 software (SPSS, Inc., Chicago, IL, USA). Con-
tinuous data are presented as mean ± standard deviation.
Categorical data are presented as percentages. Differ-
ences in serum adiponectin concentrations and AdipoRs
mRNA expression levels among groups were evaluated
using the Mann–Whitney U-test because of a skewed
distribution. Differences in AdipoRs mRNA expression
levels between the lesion and their matched normal
colon tissues in the same patient with advanced aden-
oma or CRC were analyzed using the repeated pairedt-test. Immunohistochemical staining results were ana-
lyzed comparatively using linear associations. Repeated-
measures analysis of variance with a post hoc Tukey’s
multiple comparison test was used to calculate the dif-
ferences among the means of the in vitro assay groups.
A p value <0.05 was considered significant.
Results
Serum adiponectin levels in advanced adenoma and CRC
were significantly lower than those in the control group,
regardless of BMI
As shown in Figure 1, serum adiponectin concentrations
varied according to gender. Serum adiponectin concen-
trations in females were higher after comparing each
subgroup between males and females (p <0.05). Serum
adiponectin concentrations in males with advanced ad-
enoma and CRC were significantly lower than those of
the control group (p <0.001). However, serum adiponec-
tin concentrations in patients with CRC were not signifi-
cantly different from those in patients with advanced
adenoma. No significant difference in serum adiponectin
concentrations was observed among female controls or
those with advanced adenoma or CRC.
Because there was a significant inverse correlation be-
tween serum adiponectin concentrations and BMI in males
(r = −0.282, p = 0.016), we analyzed serum adiponectin
concentrations according to BMI subgroups; i.e., above and
below the 23 kg/m2 cut off (see Additional file 1). Serum
adiponectin concentrations in the control subgroup with
BMI >23 kg/m2 were lower than those in the subgroup
with a BMI <23 kg/m2 (p <0.001). However, no significant
differences in serum adiponectin concentrations were ob-
served according to BMI in the advanced adenoma and
CRC groups.
Adiponectin in colon tissues originates from adipose
tissues through systemic flow and the adiponectin
expression pattern changes in the normal-adenoma-
carcinoma sequence
To determine whether adiponectin originated from exter-
nal adipose tissues through systemic flow or local produc-
tion, we measured adiponectin mRNA and protein levels
in colon tissues from each group and adipose tissue as a
control, as well as in HCT116 and HT29 cells as a CRC
cell line, and CCD-18Co cells as an embryonic colon
fibroblast cell line. Adiponectin mRNA was not detected
in any colon tissue or cell lines but was detected in control
adipose tissue (Figure 2a, 2b). Furthermore, adiponectin
protein was detected in both CRC and normal colon tis-
sues, but not in the respective cell lines (Figure 2c). Thus,
these findings suggest that adiponectin in CRC and nor-
mal colon tissue is of systemic origin and is not produced
locally. This result explains why neither adiponectin
mRNA nor protein was detected in the cell lines.
Figure 1 Serum adiponectin concentration according to gender in controls, and patients with advanced adenoma and CRC. Significant
gender differences were seen for each lesion. Serum adiponectin concentrations in males with advanced adenoma and CRC were significantly
lower than those in the control group. No significant differences in serum adiponectin concentration were observed among the groups in
females. * p <0.05; ** p <0.001.
Figure 2 Adiponectin mRNA and protein levels in cell lines and tissues. (a) Adiponectin mRNA expression was not detected by RT-PCR in
tissues, except for adipose tissue of controls. (b) Adiponectin mRNA expression was not detected by RT-PCR in CRC cell lines, except for the
adipose tissue of controls. (c) Adiponectin protein was detected by Western blotting in CRC and normal colon tissues, but not in cell lines. N,
normal colon tissue; C, colorectal cancer; is, carcinoma in situ; ad, advanced adenoma.
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formed to compare the adiponectin expression patterns
among normal colon, advanced adenoma, and CRC tis-
sues. Adiponectin expression in normal colon tissues was
predominantly positive in the subepithelial mesenchymal
cells of the lamina propria but not in the colonic epithelial
cells. The expression had an appearance similar to the
spindle-shaped cells that run parallel to the lining of the
epithelium (Figure 3a). However, the adiponectin expres-
sion pattern of the thin layer in the subepithelial area was
obliterated, while an indeterminate over-expression pat-
tern in stroma was seen in 71.4% of advanced adenoma
and 97.4% of CRC tissues (Figure 3b, c).AdipoRs expression in epithelium decreased in the
progression from normal tissue to advanced adenoma
We examined AdipoR1 and AdipoR2 mRNA and protein
expression levels in specimens from control, advanced
adenoma, and CRC tissues by qRT-PCR and immuno-
histochemical staining. As shown in Figure 4, AdipoR1
and AdipoR2 mRNA expression levels were significantly
lower in the advanced adenoma and CRC groups than
those in the controls. However, no difference in AdipoRs
mRNA expression levels was observed between the ad-
vanced adenoma and CRC groups.Figure 3 Immunohistochemical staining of adiponectin, AdipoR1, and
tissue (a, ×200), advanced adenoma (b, ×200) and CRC (c, ×200) differed fr
the lamina propria. (d–i) Staining for AdipoR1 (d, ×200) and AdipoR2 (g, ×2
(e, ×400) and AdipoR2 (h, ×100) showed moderate staining intensities in th
AdipoR2 (i, ×100) showed weak or no staining.AdipoR1 and AdipoR2 expression by immunohisto-
chemical staining were localized in the colon epithelium
and was positive in all (100%) of the control and ad-
vanced adenoma tissues and in 62.8% and 88.5% of CRC
tissues. The distribution and density of staining for Adi-
poRs decreased significantly in the order of normal to ad-
vanced adenoma to CRC tissues (Tables 2, 3; Figure 3d–i).
We confirmed these differences in AdipoR1 expression
between advanced adenoma and CRC in nine patients
with carcinoma in situ, which arose from advanced aden-
oma (p = 0.034, Wilcoxon’s signed-rank test), as shown in
Additional file 2 and Figure 5. No significant differences
were observed in the relationship between AdipoRs stai-
ning and the clinicopathological characteristics of CRC
such as differentiation, TNM stage, or tumor location.
Adiponectin downregulates COX-2 mRNA expression and
upregulates T-cadherin mRNA expression in HCT116 cells
Based on the changes in the adiponectin expression pat-
tern in subepithelial area and AdipoRs expression pattern
in the colonic epithelium in the normal-adenoma-car
cinoma sequence, we investigated the direct effects of adi-
ponectin on AdipoRs and EMT-associated regulators on
CRC development, progression and metastasis. The mRNA
expression levels of AdipoRs, E-cadherin, and COX-2 as
EMT regulators, and T-cadherin, not only as a tumorAdipoR2. (a–c) Localization of adiponectin staining in normal colon
om spindle-shaped cells in the subepithelial area to a diffuse area in
00) was positive in the epithelium of normal colon tissues. AdipoR1
e epithelial layer of advanced adenoma. In CRC, AdipoR1 (f, ×400) and
Figure 4 mRNA expression of AdipoR1 and AdipoR2 in controls and patients with advanced adenoma and CRC. (a, b) AdipoR1 and
AdipoR2 mRNA expression levels in advanced adenoma and CRC tissues were significantly lower than those in the control group. AdipoRs mRNA
expression levels were not significantly different between advanced adenoma and the CRC tissues. The top and bottom of the boxes are the 25th
and 75th percentiles. The difference between the quartiles is the interquartile range. The line across the middle of the box shows the median
value. * p <0.05, ** p <0.001.
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examined in HCT116 cells treated with adiponectin. Adi-
ponectin treatment downregulated COX-2 mRNA ex-
pression, upregulated T-cadherin mRNA expression in
a dose-dependent manner (Figure 6), and 20 μg/mL
adiponectin slightly upregulated AdipoR2 mRNA ex-
pression in HCT116 cells (see Additional file 3). Adipo-
nectin treatment had no effect on E-cadherin mRNA
expression levels in HCT116 cells (see Additional file 4).
Discussion
Our findings suggest several possible mechanisms for the
effect of adiponectin on the early stage of colorectal car-
cinogenesis. Adiponectin has anti-proliferative and anti-
tumorigenesis properties. A deficiency of adiponectinTable 2 Immunohistochemical staining scores for
AdipoR1
Control Advanced adenoma CRC p value
(n = 10) (n = 29) (n = 35)
Density (%) <0.001
None 0 0 13 (37.2)
Mild 0 6 (20.7) 14 (40.0)
Moderate 2 (20.0) 8 (27.6) 6 (17.1)
Intense 8 (80.0) 15 (51.7) 2 (5.7)
Distribution (%) <0.001
< 10% 0 0 13 (37.1)
10–30% 0 1 (3.4) 0 (0.0)
30–60% 0 6 (20.7) 3 (8.6)
> 60% 10 (100.0) 22 (75.9) 19 (54.3)
CRC, colorectal cancer.seems to be associated with the development of an early
neoplasm, rather than advanced CRC. Serum adiponectin
concentrations were significantly lower in male patients
with advanced adenoma than those in healthy control
males. However, no difference in serum adiponectin con-
centrations were observed between patients with ad-
vanced adenoma and CRC. These results are consistent
with studies on the anti-tumorigenesis properties of adi-
ponectin, which show that low serum adiponectin concen-
trations are strongly associated with an increased risk of
colorectal adenoma or early CRC, but not with advanced
CRC [27-29]. Additionally, the gender difference in adipo-
nectin concentrations seen in our patients has been re-
ported previously [27,30-34]. This result is consistent with
the report by Wei et al. that males with low plasmaTable 3 Immunohistochemical staining scores for
AdipoR2
Control Advanced adenoma CRC p value
(n = 10) (n = 14) (n = 26)
Density (%) <0.001
None 0 0 3 (11.5)
Mild 0 0 11 (42.4)
Moderate 2 (20.0) 8 (57.1) 9 (34.6)
Intense 8 (80.0) 6 (42.9) 3 (11.5)
Distribution (%) 0.027
< 10% 0 0 3 (11.5)
10–30% 0 0 0
30–60% 0 0 0
> 60% 10 (100.0) 14 (100.0) 23 (88.5)
CRC, colorectal cancer.
Figure 5 Representative examples of AdipoR1 immunohistochemical staining with carcinoma in situ arising from advanced adenoma (×100).
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with higher levels [21].
A second possible mechanism for the role of adiponec-
tin in colorectal neoplasm is a direct anti-tumorigenic ef-
fect. Interest in the association between adiponectin and
CRC originated from consideration of CRC as a complica-
tion of obesity [35,36]. Many reports have suggested that
adiponectin affects cancer development indirectly, via
insulin resistance [33,35,37,38]. We compared serum
adiponectin concentrations among the groups after strati-
fication by BMI, based on the inverse correlation between
obesity and serum adiponectin concentrations. Contrary
to our expectations, serum adiponectin concentrationsFigure 6 Influence of adiponectin on COX-2, T-cadherin in HCT116 ce
dose-dependent manner. (b) Expression of T-cadherin mRNA was upregulawere lower in patients with colorectal neoplasms regar-
dless of the presence of obesity, and did not differ sig-
nificantly between the overweight and normal weight
subgroups in the advanced adenoma and CRC groups.
This finding was similar to findings of previous studies,
which showed a link among obesity, CRC, and adipo-
nectin [39]. This finding suggests that adiponectin could
exert local effects on colon tissues [24,38]. We also found
that adiponectin downregulated COX-2 mRNA expres-
sion and upregulated T-cadherin mRNA expression in
colon cancer cells in a dose-dependent manner; thus, sug-
gesting direct tumor suppression. These findings support
previous reports that adiponectin directly suppresseslls. (a) Adiponectin downregulated COX-2 mRNA expression in a
ted by adiponectin in a dose-dependent manner. * p <0.05 vs. control.
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ies have demonstrated a probable direct inhibitory effect
of adiponectin in colorectal carcinogenesis. Fujisawa et al.
and Byeon et al. demonstrated the inhibition of CRC cell
growth by adiponectin using the MTT assay [42,43].
These reports suggest another role of adiponectin, in
addition to its indirect role in hormone modulation in the
metabolic environment. It is possible that adiponectin ori-
ginating from adipose tissues influences colonic tissue via
systemic blood flow. We did not detect mRNA expression
of adiponectin in any colon tissue, HCT116, and HT29
cancer cells or CCD-18Co embryonic colon myofibroblast
cells, despite the positive results in the control adipose tis-
sue. However, adiponectin was detected in colon tissue,
but not in colonic epithelial cells, by Western blotting and
immunohistochemical staining.
Adiponectin expression by immunohistochemical stain-
ing was localized to spindle-shaped cells of the subepithe-
lial thin layer surrounding each epithelial nest in normal
colon tissue. Adiponectin expression in advanced aden-
oma and CRC tissues was seen in the stroma with an
ill-defined pattern. Considering their location and morph-
ology, adiponectin-expressing cells were likely myofibro-
blasts [44-46]. Although CCD-18Co cells did not express
adiponectin as determined by Western blotting, it is pos-
sible that the spindle-shaped cells are myofibroblasts be-
cause the CCD-18Co cell line originated from an embryo.
Myofibroblasts adjacent to neoplastic cell nests express
important molecules that regulate the EMT to cancer
progression [46]. Thus, the association between adiponec-
tin and EMT regulators was investigated to determine the
pathway that mediates the direct role of adiponectin in
colorectal carcinogenesis. Among the well-known co-
lonic EMT regulators, COX-2, which originates mainly
from stromal myofibroblasts surrounding the CRC nest,
and E-cadherin, which is negatively regulated by COX-
2 in the EMT and metastasis, were examined [45,47].
T-cadherin, considered a tumor suppressor in colon,
and a third adiponectin receptor has also been investi-
gated [48-50].
The in vitro assay and immunohistochemical staining re-
sults suggest that adiponectin may prevent colorectal car-
cinogenesis and proliferation by downregulating COX-2
expression. This result may be associated with recent re-
ports that adiponectin directly inhibits colon cancer cell
proliferation via AdipoR1- and AdipoR2-mediated AMP-
activated protein kinase activation [40]. However, the role
of the AMP-activated protein kinase pathway in the regula-
tion of COX-2 expression in colon cancer cells should be
investigated further [51].
Some studies have suggested that AdipoRs expression is
greater in cancerous colonic tissues, with a compensatory
mechanism in the decline in serum adiponectin concen-
trations [37,52]. Other studies have shown that AdipoRsexpression is not different between control and colon can-
cer specimens [23]. However, AdipoRs expression in the
epithelium decreased in the progression from normal
tissue to advanced adenoma in both qRT-PCR and im-
munohistochemical staining in our study. This result
demonstrates that changes in AdipoRs expression may
mediate the effects of adiponectin according to the
normal-adenoma-carcinoma sequence [39,42]. It seems
that a large population-based study is required to exam-
ine these discrepancies.
This study had some limitations. Given the small size
of the study population, our findings should not be gen-
eralized. However, we controlled for the effects of vari-
ous confounding factors, such as metabolic syndrome,
medications, and obesity. We were unable to determine
an association between clinicopathological CRC data
and adiponectin or AdipoRs expression due to the small
sample size. Despite these limitations, this study is im-
portant because it suggests a hypothesis for the roles of
adiponectin and AdipoRs during the early stages of colo-
rectal carcinogenesis.
Conclusions
In conclusion, serum adiponectin concentrations and Adi-
poRs expression in colon tissues change reciprocally in
the normal-adenoma-carcinoma progression. Decreased
AdipoRs expression in the colonic epithelium according
to colorectal neoplasm progression was accompanied by
increased or modified adiponectin expression in the mes-
enchyme. The increased adiponectin concentration leads
to downregulation of COX-2 mRNA expression and up-
regulation of T-cadherin mRNA expression. These find-
ings offer new insights into the relationship between
adiponectin and colorectal carcinogenesis.Additional files
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BMI in controls, and patients with advanced adenoma and CRC.
Serum adiponectin concentration according to BMI in males. In the
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